<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123365</url>
  </required_header>
  <id_info>
    <org_study_id>UCI 20-50 [HS# 2021-6930]</org_study_id>
    <secondary_id>2021-6930</secondary_id>
    <nct_id>NCT05123365</nct_id>
  </id_info>
  <brief_title>An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms</brief_title>
  <official_title>An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II study evaluating the optimal dose of N-acetylcysteine (N-AC) in patients&#xD;
      with myeloproliferative neoplasms (MPN).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II open-label clinical trial determining the optimal biological dose (OBD)&#xD;
      of N-acetylcysteine in subjects with myeloproliferative neoplasms. These are subjects who&#xD;
      have a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or myelofibrosis&#xD;
      (MF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal Biological Dose (OBD) of N-Acetylcysteine</measure>
    <time_frame>From the start date of treatment until 7 days after completion of treatment or removal of treatment due to disease progression, toxicity, delay of treatment, or withdrawal of treatment, whichever came first, up to 8 weeks.</time_frame>
    <description>Determination of the optimal biological dose (OBD) will be utilized to evaluate the safety and tolerability of N-AC as a treatment for patients with MPN. Optimal biological dose is defined as the therapeutic dose that possesses the highest efficacy probability while inducing acceptable toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who achieve 30% reduction of MPN-SAF Total symptom score (MPN-TSS)</measure>
    <time_frame>7 days prior to beginning treatment until end of treatment, average of 9 weeks.</time_frame>
    <description>MPN-SAF Total symptom score (MPN-TSS) is a validated tool to objectively measure the burden of symptoms associated with MPN. Baseline TSS will be defined as the average of the daily TSS of 7 consecutive days immediately prior to beginning N-AC. The end of study MPN-TSS will be defined as the average of the daily TSS of 7 consecutive days during week 8.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>MPN</condition>
  <condition>Essential Thrombocythemia</condition>
  <condition>Polycythemia Vera</condition>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Dose Level 1 (DL1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients take N-Acetylcysteince 600 mg orally twice daily.&#xD;
This is the starting dose level for the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2 (DL2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients take N-Acetylcysteince 1200 mg orally twice daily.&#xD;
If DL1 is well tolerated, the next cohort will progress to this dose level.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3 (DL3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients take N-Acetylcysteince 1800 mg orally twice daily.&#xD;
If DL2 is well tolerated, the next cohort will progress to this dose level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Dose Level 1 (DL1)</arm_group_label>
    <arm_group_label>Dose Level 2 (DL2)</arm_group_label>
    <arm_group_label>Dose Level 3 (DL3)</arm_group_label>
    <other_name>N-AC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years of age&#xD;
&#xD;
          -  Have a diagnosis of essential thrombocythemia (ET), polycythemia vera (PV), or&#xD;
             myelofibrosis (MF) according to the 2016 WHO criteria&#xD;
&#xD;
          -  Has not taken interferon-alpha or a JAK inhibitor (such as ruxolitinib or fedratinib)&#xD;
             for treatment of MPN in the past 28 days before enrollment.&#xD;
&#xD;
          -  May continue on current MPN treatment, including aspirin, hydroxyurea, or anagrelide.&#xD;
             Therapeutic phlebotomies should continue per the patient's usual regimen.&#xD;
&#xD;
          -  Has not taken N-Acetylcysteine (N-AC) or preparations containing N-AC in the past 28&#xD;
             days before enrollment.&#xD;
&#xD;
          -  Baseline MPN-TSS score of ≥ 10 at the time of enrollment.&#xD;
&#xD;
          -  Peripheral blast count &lt;10% during Screening.&#xD;
&#xD;
          -  Free of other active or metastatic malignancies other than localized skin cancer.&#xD;
&#xD;
          -  Amenable to blood draws and symptom assessments.&#xD;
&#xD;
          -  Agree to the use of contraceptives. Female subjects of childbearing potential and&#xD;
             their male partners, or male subjects who have female partners of childbearing&#xD;
             potential, should both use an effective contraception method during the study and&#xD;
             continue to use contraception for 60 days after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) questionnaire score of ≥3&#xD;
&#xD;
          -  Currently pregnant or planning on being pregnant within the study period.&#xD;
&#xD;
          -  Currently breastfeeding.&#xD;
&#xD;
          -  Known uncontrolled active viral or bacterial infection.&#xD;
&#xD;
          -  Significant impairment of major organ function defined as&#xD;
&#xD;
               1. Serum creatinine clearance less than 50 ml/min (calculated with Cockroft-Gault&#xD;
                  formula).&#xD;
&#xD;
               2. Bilirubin more than 1.5 mg/dl except for Gilbert's disease. ALT or AST more than&#xD;
                  2X upper normal limit or has radiologic evidence of liver cirrhosis.&#xD;
&#xD;
               3. Platelets &lt; 100 × 10^9/L&#xD;
&#xD;
               4. Hgb &lt; 10 g/dL&#xD;
&#xD;
               5. ANC &lt; 0.75 × 10^9/L&#xD;
&#xD;
          -  Known history of allergic reaction to N-AC.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Fleischman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chao Family Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Fleischman, MD, PhD</last_name>
    <phone>(714) 456-8000</phone>
    <email>agf@hs.uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>University of California Irvine Medical Center</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center, University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Angela Fleischman, MD, PhD</last_name>
      <phone>714-456-8000</phone>
      <email>agf@hs.uci.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Angela G. Fleischman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>MPN</keyword>
  <keyword>Myeloproliferative Neoplasm</keyword>
  <keyword>Essential Thrombocytemia</keyword>
  <keyword>Polycythemia Vera</keyword>
  <keyword>Myelofibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

